利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

95 条记录 (耗时 0.018 秒)

    MEANS AND METHODS FOR UNIVERSAL CALIBRATION OF ANTI-FACTOR Xa TESTS
    3.
    发明公开
    MEANS AND METHODS FOR UNIVERSAL CALIBRATION OF ANTI-FACTOR Xa TESTS 审中-公开
    MITTEL UND VERFAHREN ZUR UNIVERSELLEN KALIBRIERUNG VON ANTI-FAKTOR-XA-TESTS

    公开(公告)号：EP3014282A1

    公开(公告)日：2016-05-04

    申请号：EP14732895.9

    申请日：2014-06-26

    申请人： Roche Diagnostics GmbH ,  F. Hoffmann-La Roche AG

    发明人： ACKERMANN, Friedrich ,  CALATZIS, Andreas

    IPC分类号： G01N33/86 ,  A61K38/48

    CPC分类号： C12Q1/56 ,  C12Y304/21006 ,  G01N33/86 ,  G01N2333/96444 ,  G01N2496/00 ,  G01N2500/20

    摘要： The present invention concerns diagnostic means and methods in the field of coagulation testing. In particular, it relates to a method for determining an anticoagulant activity elicited by a first anticoagulant in a sample of a subject comprising measuring a first Factor Xa activity in a body fluid test sample of said subject, measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, calculating an universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities and comparing the said parameter for the anticoagulation activity with predefined ranges of expected anticoagulation activity for at least three anticoagulants. Further provided is a computer program code assisting the method as well as a system for carrying out the said method as well as a kit.

    摘要翻译： 本发明涉及凝血试验领域的诊断手段和方法。 具体地，本发明涉及一种用于测定受试者样品中由第一抗凝血剂引起的抗凝血活性的方法，包括测量所述受试者的体液测试样品中的第一因子Xa活性，至少测量第二因子Xa活性 一个校准品样品包含针对第二抗凝血剂的预定抗凝活性，基于第一和第二测量的因子Xa活动计算包含在测试样品中的抗凝活性的通用参数，并将抗凝活性的所述参数与预定义的范围 预期至少有三种抗凝剂的抗凝活性。 还提供了一种辅助该方法的计算机程序代码以及用于执行所述方法的系统以及套件。

    HEMATOLOGICAL ASSAY AND REAGENT
    5.
    发明公开
    HEMATOLOGICAL ASSAY AND REAGENT 有权
    血液测定与试药

    公开(公告)号：EP1240528A2

    公开(公告)日：2002-09-18

    申请号：EP00991194.2

    申请日：2000-12-14

    申请人： Pentapharm AG

    发明人： GEMPELER, Patrizia, Maria ,  CALATZIS, Andreas

    IPC分类号： G01N33/86 ,  C12Q1/56

    CPC分类号： G01N33/86 ,  G01N2333/4616 ,  G01N2333/7456 ,  G01N2333/96444

    摘要： A hematological assay is described in which the blood coagulation potential of a body fluid is assessed by reacting a sample of the body fluid with an amount of an activator reagent comprising: (a) a predetermined amount of factor Xa or a hematologically equivalent mutant thereof, and (b) a predetermined amount of factor Va, a hematologically equivalent mutant thereof or an enzyme activating endogenous factor V, (c) (optionally) phospholipids. The reagent may be dry (e.g. lyophilised) or in an aqueous solution preferably buffered to a pH from 6 to 10 (preferably 7 to 8), if desired incubating, if necessary inducing coagulation by the addition of one or more coagulation accelerants such as calcium chloride, and establishing a value indicative of the coagulation potential, e.g. by measuring the time to clotting on an optical coagulometer or through use of a chromogenic substrate. It is preferred to use at (b) factor V activator from purified Russell's Viper venom (RVV-V). An activator reagent is also described containing the components mentioned above preferably in one or more buffer solutions or in dried, e.g. lyophilised form.

    DETERMINATION OF COMPONENTS ACTIVE IN PROTEOLYSIS
    6.
    发明授权
    DETERMINATION OF COMPONENTS ACTIVE IN PROTEOLYSIS 失效
    测定活性成分的组分

    公开(公告)号：EP0318571B1

    公开(公告)日：1993-03-17

    申请号：EP88906168.5

    申请日：1988-06-15

    申请人： CHROMOGENIX AB

    发明人： AURELL, Leif ,  FRIBERGER, Petter

    IPC分类号： C12Q1/56 ,  C12Q1/37

    CPC分类号： G01N33/86 ,  C12Q1/37 ,  C12Q1/56 ,  G01N2333/96444 ,  G01N2333/96461 ,  G01N2333/968 ,  G01N2333/9726 ,  G01N2400/40

    摘要： The invention relates to a freeze-dried reagent combination containing all reagents required for determination of components active in a proteolysis such as proteases and especially proenzymes, cofactors, inhibitors and activators for proteases which reagent combination is enclosed in a container such as a cuvette. The invention also relates to a new process for the preparation of such a reagent combination in which process the conditions are controlled so that all reagents can exist in one single solution which is freeze-dried without the reagent being deactivated; and the use of the reagent combination in the fields of coagulation and fibrinolysis.

    DYNAMIC CONTINUOUS FLOW ENZYME REACTOR
    7.
    发明授权
    DYNAMIC CONTINUOUS FLOW ENZYME REACTOR 失效
    动态连续流动酶反应器

    公开(公告)号：EP0353291B1

    公开(公告)日：1993-01-27

    申请号：EP89902462.4

    申请日：1989-02-01

    申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

    发明人： NEMERSON, Yale ,  TURITTO, Vincent

    IPC分类号： C12M1/40 ,  C12Q1/56

    CPC分类号： C12M21/18 ,  C12M23/06 ,  C12Q1/56 ,  G01N2333/96444 ,  G01N2333/96447 ,  G01N2333/96463 ,  G01N2333/974 ,  G01N2405/04

    摘要： A dynamic continuous flow enzyme reactor and method for carrying out and analyzing phospholipid-dependent enzyme reactions are provided. The enzyme reactor is a tubular member preferably a capillary tube, coated on its inner surface with a planar phospholipid bilayer membrane, optionally and preferably containing an enzyme or enzyme cofactor. The reactor is connectable at one end to a means for delivering fluid flow reagents to the reactor and is connectable at a second end to a means for analyzing an effluent exiting from the reactor. Preferably the enzyme cofactor in the phospholipid membrane is purified tissue factor and the fluid reagents are inactive blood clotting factors which become activated upon interaction with the phospholipid membrane through a tissue factor-mediated reaction.

    IMPROVED STABLE COAGULATION CONTROLS
    8.
    发明公开
    IMPROVED STABLE COAGULATION CONTROLS 失效
    改进的控制程序稳定血液凝固。

    公开(公告)号：EP0482088A1

    公开(公告)日：1992-04-29

    申请号：EP90911682.0

    申请日：1990-07-18

    申请人： ANALYTICAL CONTROL SYSTEMS, INC.

    发明人： SPECK, Roy, E.

    IPC分类号： C12Q1 ,  G01N33

    CPC分类号： C12Q1/56 ,  G01N33/86 ,  G01N33/96 ,  G01N2333/755 ,  G01N2333/8117 ,  G01N2333/96444 ,  G01N2333/974 ,  G01N2496/05 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/106664 ,  Y10T436/108331

    摘要： L'invention concerne des plasmas améliorés de régulation de la coagulation stable du sang, lesquels plasmas consistent en du plasma sanguin et en des quantités efficaces de (a) un tampon pour maintenir un pH physiologique, (b) un inhibiteur de protéase et (c) un hydrate de carbone de stabilisation appropriée. Des plasmas préférés de régulation contiennent également un azide de sodium et/ou thimerosal. Sont également décrits des plasmas de régulation stable ayant des niveaux élevés du facteur V et VIII comprenant un plasma du sang qui a été récupéré directement d'une source animale dans une solution contenant (a) un tampon pour maintenir un pH physiologique, (b) un inhibiteur de protéase et (c) un citrate et auquel, après élimination des cellules rouges, on a ajouté au moins environ 2 % d'un hydrate de carbone approprié de stabilisation, tel que le sucrose. Des procédés de préparation de plasma de régulation stable sont également décrits.